CMAB Biopharma (Suzhou) Inc., a biologics contract manufacturing and development organization (CDMO), has appointed Ye Shi as Head of Quality. He will be responsible for the overall management of the quality system within CMAB.

Mr. Ye Shi has worked for biopharmaceutical companies in both China and the U.S. for the past 30 years, promoting world-class quality management. Before joining CMAB, he served as the Deputy General Manager and Quality Assurance Director at QILU Pharmaceutical Co., where he successfully led the team to pass the Pre-inspection approval (PAI) of antibody drugs by the Chinese Centre for Drug Evaluation (CDE), which subsequently successfully entered commercialization. Additionally, he led the quality team to successfully pass the European QP audit, laying the foundation for clinical trials in the EU and internationally.

Dr. Yongzhong Wang, CEO of CMAB said, “We are very pleased to welcome Mr. Ye Shi to CMAB. In the Chinese biopharmaceutical and CDMO industries, quality experts like Mr. Ye Shi are very rare. He has both front-line practical experience as well as success in managing an entire company quality system both at home and abroad. We believe that his leadership will greatly strengthen CMAB’s world-class CDMO quality system and provide our customers with more outstanding services.